OC
TVRD

Oppenheimer & Co’s Tvardi Therapeutics TVRD Stock Holding History

Oppenheimer & Co’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-476
Closed -$156K – 1476
2022
Q2 		$156K Buy
476
+129
+37% +$45.3K ﹤0.01% 1301
2022
Q1 		$152K Sell
347
-30
-8% -$12.3K ﹤0.01% 1390
2021
Q4 		$165K Sell
377
-152
-29% -$76.4K ﹤0.01% 1412
2021
Q3 		$294K Buy
+529
New +$265K 0.01% 1234

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Oppenheimer & Co's TVRD Position: Q3 2022 in Review

Oppenheimer & Co sold out of Tvardi Therapeutics (TVRD) in Q3 2022, closing a stake of 476 shares — an estimated $156K sold.

Oppenheimer & Co first reported a position in TVRD in Q3 2021 and held it in 4 quarters. The position peaked at $294K in Q3 2021. 165 funds tracked by Wall St. Rank hold TVRD as of Q3 2022.

  • Oppenheimer & Co reported no remaining Tvardi Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Oppenheimer & Co sold 476 Tvardi Therapeutics shares in Q3 2022, an estimated $156K.
  • Oppenheimer & Co first reported a position in Tvardi Therapeutics in Q3 2021 and held it in 4 quarters.
  • Oppenheimer & Co's Tvardi Therapeutics position peaked at $294K in Q3 2021.
  • 165 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2022.

Based on Oppenheimer & Co's 13F filing for Q3 2022, filed 14 Nov 2022.